Arcturus Therapeutics Reports $1.03 Per Share Loss for Q4
ARCT sits 34% above its 52-week low of $5.85.
Summary
Arcturus Therapeutics announced a loss of $1.03 per share for the fourth quarter. This financial update provides key insight into the company's recent operational performance. While the headline does not provide context on analyst estimates, a reported loss is a material data point for investors. Traders will be evaluating this result against market expectations and its potential impact on future operations and stock valuation.
At the time of this announcement, ARCT was trading at $7.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $224.8M. The 52-week trading range was $5.85 to $24.17. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.